These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 39071291)
21. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947 [TBL] [Abstract][Full Text] [Related]
22. Characterizing CDK12-Mutated Prostate Cancers. Rescigno P; Gurel B; Pereira R; Crespo M; Rekowski J; Rediti M; Barrero M; Mateo J; Bianchini D; Messina C; Fenor de la Maza MD; Chandran K; Carmichael J; Guo C; Paschalis A; Sharp A; Seed G; Figueiredo I; Lambros M; Miranda S; Ferreira A; Bertan C; Riisnaes R; Porta N; Yuan W; Carreira S; de Bono JS Clin Cancer Res; 2021 Jan; 27(2):566-574. PubMed ID: 32988971 [TBL] [Abstract][Full Text] [Related]
23. Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135 [TBL] [Abstract][Full Text] [Related]
24. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960 [TBL] [Abstract][Full Text] [Related]
25. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090 [TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720 [TBL] [Abstract][Full Text] [Related]
29. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation. Muvaffak A; Coleman KG Front Oncol; 2024; 14():1380633. PubMed ID: 38807759 [TBL] [Abstract][Full Text] [Related]
31. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147 [TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108 [TBL] [Abstract][Full Text] [Related]
33. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. Mekonnen N; Yang H; Shin YK Front Oncol; 2022; 12():880643. PubMed ID: 35785170 [TBL] [Abstract][Full Text] [Related]
34. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694 [TBL] [Abstract][Full Text] [Related]
35. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Pacheco-Barcia V; Muñoz A; Castro E; Ballesteros AI; Marquina G; González-Díaz I; Colomer R; Romero-Laorden N Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740616 [No Abstract] [Full Text] [Related]
36. Clinical assays for assessment of homologous recombination DNA repair deficiency. Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552 [TBL] [Abstract][Full Text] [Related]
37. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Antonarakis ES; Gomella LG; Petrylak DP Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685 [TBL] [Abstract][Full Text] [Related]
38. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115 [TBL] [Abstract][Full Text] [Related]